THYMIC STROMAL LYMPHOPOIETIN AS A PREDICTOR OF HYPERTROPHIC CHANGES IN THE NASAL MUCOSA IN CHILDREN WITH ATOPIC BRONCHIAL ASTHMA AND ALLERGIC RHINITIS

2020 ◽  
Vol 99 (4) ◽  
pp. 71-78
Author(s):  
S.V. Krasilnikova ◽  
◽  
D.Yu. Ovsyannikov ◽  
T.I. Eliseeva ◽  
E.V. Tush ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Bronchial Asthma ◽  
Nasal Mucosa ◽  
Thymic Stromal Lymphopoietin ◽  
Atopic Bronchial Asthma ◽  
Hypertrophic Changes

scholarly journals Periostin as a Biomarker of Allergic Inflammation in Atopic Bronchial Asthma and Allergic Rhinitis (a Pilot Study)

2020 ◽  
Vol 12 (5) ◽  
pp. 37
Author(s):  
S.V. Krasilnikova ◽  
E.V. Tush ◽  
P.A. Frolov ◽  
D.Yu. Ovsyannikov ◽  
A.B. Terentyeva ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Pilot Study ◽  
Bronchial Asthma ◽  
Allergic Inflammation ◽  
Atopic Bronchial Asthma

scholarly journals MODERN VIEW ON THE PROBLEM OF HOUSE DUST MITES SENSITIZATION

2013 ◽  
Vol 10 (5) ◽  
pp. 3-12
Author(s):  
O M Kurbacheva ◽  
K S Pavlova ◽  
E A Melnikova
Keyword(s):  
Allergic Rhinitis ◽  
Bronchial Asthma ◽  
House Dust ◽  
House Dust Mites ◽  
Dust Mites ◽  
Vital Activity ◽  
Modern View ◽  
Atopic Bronchial Asthma

Dermatophagoides pteronissinus, Dermatophagoides farinea and their products of vital activity are the main allergenic components of house dust. The only pathogenetic and effective method of treatment of patients with house dust mites induced allergic rhinitis and atopic bronchial asthma according to positions of evidencebased medicine is allergenspecific immunotherapy (ASIT) with house dust mites (Dermatophagoides pteronissinus, Dermatophagoides farinea) allergens. Modern data on prevalence of a sensitization to house dust mites at patients with respiratory manifestations of allergy are presented in the review, questions of carrying out ASIT by various methods with application of the standardized allergens, its efficiency and safety are discussed.

Patient with polymorbid pathology. Possibilities of therapy with monoclonal antibodies

2021 ◽  
Vol 18 (2) ◽  
pp. 123-130
Author(s):  
Natalia G. Astafyeva ◽  
Ekaterina N. Udovichenko
Keyword(s):  
Allergic Rhinitis ◽  
Monoclonal Antibodies ◽  
Bronchial Asthma ◽  
Severe Disease ◽  
Therapeutic Interventions ◽  
Response To Treatment ◽  
Atopic Bronchial Asthma ◽  
Target Organs ◽  
Immune Mediated ◽  
Number Of Patients

With the widespread increase in the number of patients with allergic pathology, doctors in clinical practice increasingly have to observe the simultaneous development of several nosological forms in the same patient. Frequent occurrence of a combination of lesions of the skin and respiratory tract in patients with atopy (atopic dermatitis, allergic rhinitis, and atopic bronchial asthma) is traditionally considered within the framework of comorbidity and suggests a number of therapeutic interventions given the similarity of the pathogenesis. However, phenotypic or endotypic differences exist between patients (e.g., triggers, age, persistence of manifestations, degree and type of inflammation, severity of symptoms, and response to treatment), for which it is more correct to use the term multimorbidity. The strategy of precision medicine for patients with several immune-mediated diseases should focus on identifying not only the general features of the disease, but also the pathogenetic mechanisms in the target organs. Because of these differences, the sensitivity to therapeutic interventions by target organs can vary. Herein, a clinical case of a patient with comorbid pathology ― chronic spontaneous urticaria, allergic rhinitis, and bronchial asthma ―was analyzed. Respiratory manifestations (rhinitis and asthma) were mild to severe. Chronic urticaria had the most severe disease course and resistant to antihistamines, which are considered first and second lines of drugs according to federal and international clinical guidelines that required the use of monoclonal antibodies. Anti-IgE therapy with omalizumab had a rapid and complete effect on urticaria symptoms, but respiratory symptoms were less responsive to treatment. In patients with multimorbid pathology, therapy should be individualized in terms of targeted drugs and their dosage.

Hypertrophic and polyposis synonasal mucosa (SM) changes in children with atopic bronchial asthma (BA) and allergic rhinitis (AR)

2021 ◽  
Author(s):  
Igor A. Klimanov ◽  
Nikolay Eruslankin ◽  
Anastasija Vagina ◽  
Tatyana Eliseeva ◽  
Svetlana Krasilnikova ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Bronchial Asthma ◽  
Atopic Bronchial Asthma

scholarly journals Features of local inflammation of nasal mucosa in children with bronchial asthma

2020 ◽  
Vol 19 (3) ◽  
pp. 22-30
Author(s):  
S. V. Krasil’nikova ◽  
◽  
T. I. Eliseeva ◽  
E. V. Tush ◽  
E. V. Bol’shova ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Bronchial Asthma ◽  
Nasal Mucosa ◽  
Allergic Inflammation ◽  
Acute Stage ◽  
Upper Respiratory Tract ◽  
Local Inflammation ◽  
Inflammatory Processes ◽  
Nasal Secretions ◽  
Relationship Of

Bronchial asthma (BA) is often associated with chronic inflammatory processes in the nasal mucosa; these processes give rise to allergic rhinitis (AR), chronic rhinosinusitis, adenoiditis and polypous rhinosinusitis. Due to their multiple symptoms, these diseases of the upper respiratory tract, especially allergic rhinitis, are often difficult to verify in patients with asthma. The aim of the study was to assess the features of local inflammation of the nasal mucosa in patients with BA and AR. Patients and methods. 93 children with BA were examined. General clinical, allergological, functional examination, measurement of endonasal temperature and determination of IgE and IL4 content in nasal secretions were performed. Results. Children with BA have lower values of endonasal temperature than healthy ones. There was a tendency to decrease endonasal temperature as the symptoms of AR increased. In the acute stage of AR, the temperature values were lower than in the remission stage, р = 0,02. The addition of infectious inflammation of the nasal mucosa in children with AD was accompanied by an increase in endonasal temperature, р = 0,04. The increase of the content of nasal IgE in acute AR – 115,6 (49,9; 181,2) ME/mg, compared to the remission period to 24,9 (6,2; 43,7) ME/mg. Exacerbation of AR was associated with increased IL4 to 109,7 (54,2; 165,2) PG/mg, in the period of remission – 34,4 (12,0; 56,8) PG/mg. The increase of these biomarkers of allergic inflammation have a correlative relationship, R = 0,44, p = 0,002. The relationship of IL4 content with endonasal temperature, R = 0,44 р = 0,02 was established. Conclusion. Patients with BA and AR showed a decrease in endonasal temperature compared to healthy ones. Exacerbation of AR in children with BA characterized by an increase in the content of nasal IgE and IL4 and a decrease in endonasal temperature, which allows us to consider these indicators as biomarkers of activation of allergic inflammation.

scholarly journals Dynamics of the cytokine profile in achieving the therapeutic effect of allergen-specific immunotherapy in children with allergic rhinitis and bronchial asthma

2021 ◽  
Vol 66 (5) ◽  
pp. 176-182
Author(s):  
O. V. Skorokhodkina ◽  
S. A. Arkhipova ◽  
T. V. Klykova ◽  
G. M. Zaynetdinova ◽  
E. B. Kruglova ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Bronchial Asthma ◽  
Specific Immunotherapy ◽  
Allergic Diseases ◽  
Cytokine Profile ◽  
Allergen Specific Immunotherapy ◽  
Atopic Bronchial Asthma ◽  
Regulatory T Lymphocytes ◽  
Ige Mediated ◽  
Medical University

Allergen-specific immunotherapy is a pathogenetic method for the treatment of IgE-mediated allergic diseases.Objective. To evaluate effectiveness of allergen-specific immunotherapy in 471 children with allergic rhinitis and bronchial asthma, as well to analyze the dynamics of the cytokine profile at baseline and 1 year after the start of treatment in 86 children. The research was supported by a grant from the International Scientific Council for Young Scientists of Kazan State Medical University.Results. Analysis of the data obtained demonstrated that allergen-specific immunotherapy is a highly effective method of treating children with allergic rhinitis and atopic bronchial asthma. The dynamics of the level of the studied cytokines during treatment indirectly indicates an increase in the functional activity of adaptive subpopulations of regulatory T-lymphocytes (T-reg) and B-lymphocytes (B-reg) with a decrease in the activity of Th2 lymphocytes, which may indicate the reconstruction of the immune response and possible disease-modifying effect.

Atopic dermatitis: new horizons of therapy

2019 ◽  
Vol 1 (7) ◽  
pp. 29-32 ◽  
Author(s):  
L. S. Kruglova ◽  
E. M. Gensler
Keyword(s):  
Blood Pressure ◽  
Immune Response ◽  
Allergic Rhinitis ◽  
Atopic Dermatitis ◽  
Targeted Therapy ◽  
Inflammatory Response ◽  
Bronchial Asthma ◽  
New Horizons ◽  
The Past

Over the past decades, the first breakthrough milestone in the treatment of severe forms of atopic dermatitis (AD) has been targeted therapy aimed at inhibiting IL-4 and IL-13. This was made possible thanks to advances in the understanding of the pathogenesis of AD, the driver of which is the Th2-type immune response, which also underlies such manifestations of atopy as bronchial asthma, allergic rhinitis, and polynosis. In the case of the Th2-type immune response, cytokines IL-4 and IL-13 are secreted, which are the main promoters of the inflammatory response in AD. Inhibition of IL-4 and IL-13 leads to the prevention of inflammation and is an effective approach to therapy. The use of therapy aimed at inhibition of cytokines allows you to effectively cope with the manifestations of severe and moderately severe blood pressure.

Sign in / Sign up

Export Citation Format

Share Document